Last checked at 5 Dec 2017 07:00
OXFORD BIODYNAMICS PLC
EXERCISE OF WARRANTS, DIRECTOR DEALING AND TOTAL VOTING RIGHTS
London, 5 December 2017: Oxford BioDynamics Plc (AIM: OBD) (the "Company") announces that it has received notice from Wentworth Limited ("Wentworth") of the exercise of 689,441 warrants in exchange for the issue of 689,441 ordinary shares of 1 pence each ("Ordinary Shares") (the "New Ordinary Shares"). The warrant exercise was effected at the nominal price of 1 pence per Ordinary Share and, in accordance with the terms of the warrant instrument, Wentworth has simultaneously waived its subscription rights to the balance of 1,032,523 warrant shares previously held.
Warrants over 1,721,964 Ordinary Shares were granted to Wentworth on 30 November 2016 in consideration for Wentworth procuring placees pursuant to the placing which took place on 6 December 2016, and general corporate and strategic advice. David Williams, the Company's Chairman, is the beneficial owner of Wentworth.
Following exercise of these warrants, through his beneficial ownership of Wentworth, David Williams will be interested in a total of 1,322,352 Ordinary Shares of 1 pence each in the Company, representing approximately 1.52% of the Company's issued share.
Application will be made for the New Ordinary Shares, which rank pari passu in all respects with the Company's existing Ordinary Shares, to be admitted to trading on AIM which is expected to occur on or around 12 December 2017.
Following issue of the New Ordinary Shares, the Company's total issued share capital will consist of 86,787,669 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 86,787,669. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details:
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | David Williams |
2 | Reason for the notification | |
a) | Position/status | Non-Executive Chairman |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Oxford BioDynamics Plc |
b) | LEI | 2138005Y1TK258O5U928 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 1 pence each
ISIN: GB00BD5H8572 |
b) | Nature of the transaction | Exercise of warrants |
c) | Price(s) and volume(s) | 1 pence per ordinary share
689,441 ordinary shares |
d) | Aggregated information - Aggregated volume - Price
| N/A |
e) | Date of the transaction | 4 December 2017
|
f) | Place of the transaction | London Stock Exchange, AIM (XLON) |
For further details, contact:
Oxford BioDynamics Plc | +44 (0)1865 518910 | |
Christian Hoyer Millar, CEO | ||
Paul Stockdale, CFO | ||
Stifel Nicolaus Europe Limited | +44 (0)20 7710 7600 | |
Nominated Advisor and Broker | ||
David Arch | ||
Jonathan Senior | ||
Peter Lees | ||
Ben Maddison | ||
Shore Capital | +44 (0)20 7408 4090 | |
Joint Broker | ||
Edward Mansfield | ||
FTI Consulting | +44 (0)20 3727 1000 | |
Financial Public Relations Advisor | ||
Julia Phillips | ||
Brett Pollard | ||
Natalie Garland-Collins |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue-generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.